Latest FDA
ORION-1: 1-Year Follow-Up Data Affirms 2-dose Regimen Using 300 mg of Inclisiran For Persistent LDL-C Lowering
A randomized, double blind, placebo-controlled, phase II clinical trial studying the effect…
Total Event Analysis from REDUCE-IT Showcases a Substantial Reduction in the Burden of Ischemic Events, Experts Debate Possible Mechanisms of Action of Icosapent Ethyl
The total event analysis from the REDUCE-IT trial, presented at ACC 2019…
HeartMate3 Found to be More Superior Than Other LVADs on Endpoints of Stroke, Pump Thrombosis and Bleeding Complications
The largest LVAD trial ever to be performed, led by Dr. Mandeep…
COAPT Analysis Affirms Quality of Life Advantage of MitraClip for Secondary MR
NEW ORLEANS -- Transcatheter repair of functional mitral regurgitation (or secondary MR)…
U.S. Food and Drug Administration (FDA) Continues To Investigate Recall of Contaminated Blood Pressure Medication
The US food and drug Administration (FDA) has recently been conducting an…